ZILUCOPLAN
Zilucoplan 16.6 mg/0.416 mL injection, 28 x 0.416 mL syringes
ZILUCOPLAN (15285L)
15285L
Manner of administration:Injection
Restriction
Indication: Bridging therapy for generalised myasthenia gravis (gMG)
Restriction
Indication: Treatment refractory generalised myasthenia gravis (gMG)
Treatment phase: Initial treatment - Treatment refractory gMG patients
Restriction
Indication: Treatment refractory generalised myasthenia gravis (gMG)
Treatment phase: Continuing treatment - Treatment refractory gMG patients
Restriction
Indication: Treatment refractory generalised myasthenia gravis (gMG)
Treatment phase: Transitioning from non-PBS to PBS-subsidised treatment - Grandfathering treatment
- Treatment refractory gMG patients
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 5 | DPMQ: $21,443.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Zilbrysq | |||||